Compile Data Set for Download or QSAR
Report error Found 253 Enz. Inhib. hit(s) with all data for entry = 8828
TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421623(US10508086, Example 213 | US10995073, Example 213)
Affinity DataEC50:  29nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM205480(PDD00017238 (5) | US10508086, Example 90 | US10995...)
Affinity DataEC50:  40nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421626(US10508086, Example 216 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  51nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421498(US10508086, Example 88 | US10995073, Example 88)
Affinity DataEC50:  53nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421618(US10508086, Example 208 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  54nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421497(US10508086, Example 87 | US10995073, Example 87)
Affinity DataEC50:  68nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421518(US10508086, Example 108 | US10995073, Example 108)
Affinity DataEC50:  69nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421577(US10508086, Example 167 | BDBM495207)
Affinity DataEC50:  74nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421517(US10508086, Example 107 | US10995073, Example 107)
Affinity DataEC50:  86nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421573(BDBM495203 | US10508086, Example 163 | 3-[5-(Diflu...)
Affinity DataEC50:  90nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421584(US10508086, Example 174 | 3-[5-(difluoromethyl)-1,...)
Affinity DataEC50:  91nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421580(US10508086, Example 170)
Affinity DataEC50:  92nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421578(3-[5-(Difluoromethyl)-1,3,4-thiadiazol-2-yl]-6-flu...)
Affinity DataEC50:  99nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421610(US10508086, Example 200 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  112nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421622(US10508086, Example 212 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  129nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421617(US10508086, Example 207 | US10995073, Example 207)
Affinity DataEC50:  133nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421555(US10508086, Example 145 | 3-(Cyclopropanecarbonyl)...)
Affinity DataEC50:  134nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421522(US10508086, Example 112 | US10995073, Example 112)
Affinity DataEC50:  140nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421583(US10508086, Example 173 | US10995073, Example 173)
Affinity DataEC50:  141nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421521(US10508086, Example 111 | US10995073, Example 111)
Affinity DataEC50:  147nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421493(US10508086, Example 83 | US10995073, Example 83)
Affinity DataEC50:  151nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421603(US10508086, Example 193 | US10995073, Example 193)
Affinity DataEC50:  153nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421492(US10508086, Example 82 | US10995073, Example 82)
Affinity DataEC50:  155nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421627(US10508086, Example 217 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  156nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421624(US10508086, Example 214 | 2-[3-[5-(Difluoromethyl)...)
Affinity DataEC50:  165nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421625(US10508086, Example 215 | US10995073, Example 215)
Affinity DataEC50:  170nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421509(US10508086, Example 99 | US10995073, Example 99)
Affinity DataEC50:  202nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421574(US10508086, Example 164 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  203nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421512(US10508086, Example 102 | US10995073, Example 102)
Affinity DataEC50:  212nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421540(US10508086, Example 130 | 3-(Cyclopropanecarbonyl)...)
Affinity DataEC50:  218nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421575(US10508086, Example 165 | N-(1-Cyanocyclopropyl)-3...)
Affinity DataEC50:  234nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421520(US10508086, Example 110 | US10995073, Example 110)
Affinity DataEC50:  234nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421526(US10508086, Example 116 | 6-Fluoro-1-methyl-N-(1-m...)
Affinity DataEC50:  245nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421511(US10508086, Example 101 | US10995073, Example 101)
Affinity DataEC50:  246nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421585(US10508086, Example 175 | US10995073, Example 175)
Affinity DataEC50:  250nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421572(US10508086, Example 162 | US10995073, Example 162)
Affinity DataEC50:  260nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421541(US10508086, Example 131 | 3-(4-Fluorobenzoyl)-N-(1...)
Affinity DataEC50:  261nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421510(US10508086, Example 100 | US10995073, Example 100)
Affinity DataEC50:  265nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421515(US10508086, Example 105 | US10995073, Example 105)
Affinity DataEC50:  269nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421527(US10508086, Example 117 | US10995073, Example 117)
Affinity DataEC50:  275nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421562(US10508086, Example 152 | US10995073, Example 152)
Affinity DataEC50:  275nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421514(US10508086, Example 104 | US10995073, Example 104)
Affinity DataEC50:  280nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421513(US10508086, Example 103 | US10995073, Example 103)
Affinity DataEC50:  284nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421591(US10508086, Example 181 | US10995073, Example 181)
Affinity DataEC50:  291nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421592(US10508086, Example 182 | BDBM495222)
Affinity DataEC50:  309nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421609(US10508086, Example 199 | US10995073, Example 199)
Affinity DataEC50:  314nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421620(US10508086, Example 210 | 3-[5-(Difluoromethyl)-1,...)
Affinity DataEC50:  349nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421437(US10508086, Example 28 | US10995073, Example 28)
Affinity DataEC50:  352nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421579(US10508086, Example 169 | BDBM495209 | 3-[5-(Diflu...)
Affinity DataEC50:  355nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421494(US10508086, Example 84 | US10995073, Example 84)
Affinity DataEC50:  359nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

Displayed 1 to 50 (of 253 total ) | Next | Last >>
Jump to: